CN114369060B - 吲哚胺2,3-双加氧酶抑制剂及其在制备抗肿瘤药物中的应用 - Google Patents
吲哚胺2,3-双加氧酶抑制剂及其在制备抗肿瘤药物中的应用 Download PDFInfo
- Publication number
- CN114369060B CN114369060B CN202011100808.9A CN202011100808A CN114369060B CN 114369060 B CN114369060 B CN 114369060B CN 202011100808 A CN202011100808 A CN 202011100808A CN 114369060 B CN114369060 B CN 114369060B
- Authority
- CN
- China
- Prior art keywords
- nicotinic acid
- ido1
- tumor
- inhibitor
- acid derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims description 18
- 229940041181 antineoplastic drug Drugs 0.000 title claims description 17
- 238000002360 preparation method Methods 0.000 title claims description 7
- 239000003112 inhibitor Substances 0.000 title abstract description 33
- IHWDSEPNZDYMNF-UHFFFAOYSA-N 1H-indol-2-amine Chemical compound C1=CC=C2NC(N)=CC2=C1 IHWDSEPNZDYMNF-UHFFFAOYSA-N 0.000 title description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000003814 drug Substances 0.000 claims abstract description 17
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 14
- 229940044665 STING agonist Drugs 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims abstract description 7
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical group C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 57
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 abstract description 55
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 abstract description 54
- 241000699670 Mus sp. Species 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 18
- 201000011510 cancer Diseases 0.000 abstract description 16
- 230000002401 inhibitory effect Effects 0.000 abstract description 16
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract description 10
- WDGXIUUWINKTGP-UHFFFAOYSA-N 3-(3-pyridinyl)propanoic acid Chemical class OC(=O)CCC1=CC=CN=C1 WDGXIUUWINKTGP-UHFFFAOYSA-N 0.000 abstract description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract description 7
- 230000012010 growth Effects 0.000 abstract description 7
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 abstract description 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 abstract description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 abstract description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 abstract description 6
- 230000003013 cytotoxicity Effects 0.000 abstract description 3
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 3
- 239000002532 enzyme inhibitor Substances 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 229940125532 enzyme inhibitor Drugs 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 40
- 230000005764 inhibitory process Effects 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 20
- 238000002474 experimental method Methods 0.000 description 14
- 238000009169 immunotherapy Methods 0.000 description 9
- 229940043367 IDO1 inhibitor Drugs 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229960004799 tryptophan Drugs 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- -1 nicotinic acid derivative (derivative of 3-pyridine propionic acid Chemical class 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 150000002814 niacins Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 description 2
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- BYHJHXPTQMMKCA-QMMMGPOBSA-N N-formyl-L-kynurenine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)C1=CC=CC=C1NC=O BYHJHXPTQMMKCA-QMMMGPOBSA-N 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000008088 immune pathway Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 2
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- XHLKOHSAWQPOFO-UHFFFAOYSA-N 5-phenyl-1h-imidazole Chemical compound N1C=NC=C1C1=CC=CC=C1 XHLKOHSAWQPOFO-UHFFFAOYSA-N 0.000 description 1
- GEDJUAKXFJRZSG-UHFFFAOYSA-N 7-[3-[(3-acetylphenoxy)methyl]-1,5-dimethylpyrazol-4-yl]-3-(3-naphthalen-1-yloxypropyl)-1H-indole-2-carboxylic acid Chemical compound CC(=O)c1cccc(OCc2nn(C)c(C)c2-c2cccc3c(CCCOc4cccc5ccccc45)c([nH]c23)C(O)=O)c1 GEDJUAKXFJRZSG-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000008096 B7-H1 Antigen Human genes 0.000 description 1
- 108010074708 B7-H1 Antigen Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108010069941 DNA receptor Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940105657 catalase Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 1
- 235000019245 violaxanthin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
- C07D213/34—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于生物医药技术领域,发明了一类吲哚胺2,3‑双加氧酶IDO1的抑制剂,即烟酸衍生物(3‑吡啶丙酸的衍生物)。该类3‑吡啶丙酸的衍生物能有效抑制吲哚胺2,3‑双加氧酶IDO1催化色氨酸代谢,在人源癌细胞中能显著抑制高表达的IDO1酶活性,而且细胞毒性低。这些烟酸衍生物作为IDO1酶的抑制剂单独使用能显著抑制小鼠移植肿瘤生长,其与先天免疫通路STING激动剂联合使用/或与免疫检查点抑制剂联合使用,抑制肿瘤生长药效更佳,安全性也很好。因此,这类烟酸衍生物在制备免疫抗肿瘤药物中具有广阔的应用前景。
Description
技术领域
本发明属于生物医药技术领域具体涉及一类烟酸衍生物对吲哚胺2,3-双加氧酶IDO1的抑制剂其在制备免疫抗肿瘤药物中的应用
背景技术
肿瘤是一类严重危害人类生命健康的重大疾病之一,表现为细胞过度增殖和分化异常。据WHO统计,全球范围内每年癌症病例可能增加到2400万。与此同时,癌症给全球经济造成了巨大的负担。肿瘤免疫治疗是继手术、放疗、化疗后的新兴肿瘤治疗方式。它是一种利用刺激或增强人体自身免疫***的力量来预防、控制和消灭癌症的癌症治疗方法。与传统的肿瘤治疗方法相比,免疫治疗具有自身特有的优势,可以提高传统治疗的疗效,减轻传统治疗带来的不良反应等。先天免疫***激动剂、免疫检测点阻断剂和细胞免疫治疗是目前免疫治疗的主要研究领域。基于代谢调控的肿瘤免疫治疗策略,可以提高免疫治疗的有效性,让更多的患者受益,肿瘤代谢的调控为改善肿瘤免疫治疗开辟了新方向。
人体的免疫***负责识别自身与非自身,从而保护人体免受外源性和内源性疾病的侵害。人体免疫***由白细胞和淋巴器官以及淋巴组织构成,包括胸腺、脾脏、扁桃体、***、***和骨髓,免疫***通过识别并消除多种威胁来保持机体的持续稳态。癌症免疫疗法是指通过引入疫苗、细胞因子、抗体或转移的免疫细胞本身来刺激针对癌细胞的免疫***。免疫疗法在肿瘤治疗上的成功,例如免疫检查点抑制剂和CAR-T细胞疗法,已经确立了它在癌症治疗中的作用。癌症是使用多种机制来选择宿主-肿瘤免疫相互作用,从而导致免疫逃逸。在过去的几年中,我们对宿主-肿瘤相互作用的研究不断有新的进展,产生了各种有前景的免疫治疗方法。
吲哚胺2,3-双加氧酶(IDO1)是一种单体血红素蛋白,分子量为45KD。IDO1能对具有吲哚环的分子进行催化,因此被称为吲哚胺2,3-双加氧酶。IDO 1是色氨酸代谢途径中的关键限速代谢酶。大量研究表明IDO1在多种类型的人类癌症中高度表达,随后导致色氨酸代谢产物的积累,造成机体对肿瘤抗原的免疫耐受,最终导致肿瘤的免疫逃逸。许多临床前和临床试验研究表明IDO1抑制剂是对抗多种癌症的有效工具。目前,IDO1抑制剂***的临床研究正在进行,它们可以有效激活肿瘤浸润性T细胞和/或减少肿瘤驻留性免疫抑制性调节性T细胞,从而提高人体免疫,达到抗肿瘤的目的。基于IDO1在肿瘤免疫治疗中的重要作用且目前没有上市用于肿瘤治疗的IDO1抑制剂,因此,在新的IDO1抑制剂的筛选、及其基于IDO1酶抑制剂的抗肿瘤药物研究具有重要的意义。
环二核苷酸合成酶(cGAS)是先天性免疫通路中重要的细胞质DNA感受器。cGAS催化体内ATP和GTP合成cGAMP,cGAMP作为二级信使分子通过内质网膜上的STING蛋白通路诱导干扰素IFN-β和其他细胞因子的产生,调节下游蛋白质表达,诱导细胞生长停滞和凋亡,产生抗病毒效应。STING通路可以调节免疫原性肿瘤的先天免疫识别,促进干扰素的抗肿瘤作用。IFN-γ在体内通过TRAIL(tumor necrosis factor-related apoptosis-inducingligand)发挥抗肿瘤作用,促进肿瘤细胞凋亡。cGAMP是先天免疫反应的关键刺激物,是STING的内源性激活剂,具有免疫抗肿瘤作用。
本研究发明了一类创新的吲哚胺2,3-双加氧酶IDO1的抑制剂,即烟酸衍生物(3-吡啶丙酸的衍生物)。该类3-吡啶丙酸的衍生物能有效抑制吲哚胺2,3-双加氧酶IDO1催化色氨酸代谢,在人源癌细胞中能显著抑制高表达的IDO1酶活性,而且细胞毒性较低。这些烟酸类似物作为IDO1酶的抑制剂单独使用能显著抑制小鼠移植肿瘤生长,其与先天免疫通路STING激动剂联合使用/或与免疫检查点抑制剂联和使用/或与抗肿瘤化药联合使用,抑制肿瘤生长药效更佳,安全性也很好。因此,这类烟酸衍生物在制备免疫抗肿瘤药物中具有广阔的应用前景。
发明内容
本发明提供了一种创新的吲哚胺2,3-双加氧酶IDO1的抑制剂,即烟酸衍生物(3-吡啶丙酸的衍生物)。该类3-吡啶丙酸的衍生物能有效抑制吲哚胺2,3-双加氧酶IDO1催化色氨酸代谢,在人源癌细胞中能显著抑制高表达的IDO1酶活性,而且细胞毒性较低。这些烟酸衍生物作为IDO1酶的抑制剂单独使用能显著抑制小鼠移植肿瘤生长,其与先天免疫通路STING激动剂或免疫检查点抑制剂联合使用,抑制肿瘤生长药效更佳,安全性也很好。因此,这类烟酸衍生物在制备免疫抗肿瘤药物中具有广阔的应用前景。
具体发明内容特征为:
1、烟酸衍生物(3-吡啶丙酸的衍生物),是新型吲哚胺2,3-双加氧酶IDO1的抑制剂。烟酸衍生物的具体特征为:以烟酸为结构母核,利用羧酸等排体的方式进行引入S,N,O,F等易于形成氢键的原子,增强这些抑制剂与IDO1酶蛋白分子的结合力,稳定抑制剂与IDO1蛋白分子形成的复合物,增加抑制IDO1酶活性效果。具体烟酸衍生物举例见附图1(烟酸衍生物(1-10)结构式及其名称)。
2、烟酸衍生物(3-吡啶丙酸的衍生物)在制备抗肿瘤药物中的应用。所述的抗肿瘤药物,应用于治疗各种类型的肿瘤,包括但不于结直肠癌、乳腺癌、睾丸癌、卵巢癌、***癌、肺癌、鼻咽癌、食道癌、恶性淋巴瘤、头颈部癌、甲状腺癌、成骨肉瘤、膀胱癌、子***、和生殖细胞瘤等。
3、烟酸衍生物(3-吡啶丙酸的衍生物)与免疫通路STING激动剂联合(包括复合物)在制备抗肿瘤药物中的应用。STING激动剂包括但不限于cGAMP及其衍生物。所述的抗肿瘤药物,应用于治疗各种类型的肿瘤。
4、烟酸衍生物(3-吡啶丙酸的衍生物)与免疫检查点抑制剂联合用药在制备抗肿瘤药物中的应用。免疫检查点抑制剂包括但不限于抗PD1/PD-L1、抗CD-47、抗VEGF、抗CTLA-4等单克隆抗体及其单克隆抗体的纳米抗体;所述的抗肿瘤药物,应用于治疗各种类型的肿瘤。
5、烟酸衍生物(3-吡啶丙酸的衍生物)与化疗抗肿瘤药物联合用药在制备抗肿瘤药物中的应用。化疗药物包括但不限于铂类金属药物、5-氟尿嘧啶、紫山醇等抗肿瘤药物,应用于治疗各种类型的肿瘤。
6、烟酸衍生物(3-吡啶丙酸的衍生物)在制备抗肿瘤药物中的应用,包含不同规格的单位制剂及药学上可接受的药物制剂,包括但不限于静脉注射、肌肉注射、皮下注射、静脉滴注、鼻腔滴注、口服等中的一种或多种,进行上述相关肿瘤的治疗。
附图说明
图1为烟酸衍生物(1-10)结构式及其名称。
具体实施方式
下面通过实施例具体说明本发明的内容。在本发明中,以下所述的实施例是为了更好地阐述本发明,并不是用来限制本发明的范围。
实施例1:烟酸衍生物对IDO1金属酶的抑制作用研究
所有生物化学试剂均为分析纯,购于Sigma-Aldrach。烟酸衍生物1-10的结构式及其英文名称见附图1.
1、吲哚胺2,3-双加氧酶1(IDO1)按照文献方法制备
选择pGEX-6P-1作为构建人源IDO1表达质粒的载体,带有GST融合标签的IDO1蛋白在大肠杆菌中可容表达,IDO1融合蛋白使用GST亲和柱进行吸附纯化且蛋白纯度极高,采用重组HRV 3C蛋白酶进行酶切GST标签蛋白,在16℃的条件下酶过夜,酶切后的IDO1蛋白经二次使用Glutathione Sepharose亲和柱纯化,得到电泳纯蛋白,经SDS-Page和质谱鉴定。SDS-PAGE显示IDO1蛋白纯度高于95%,MALDI-TOF质谱进一步确认了IDO1的分子量为45KD,这与理论分子量相吻合;紫外可见光谱表征显示特征吸收峰为404nm,电化学还原电位为-0.37V。实验结果证明,我们成功的获得了高纯度的人源IDO1蛋白,为后续IDO1抑制剂筛选及酶活性相关实验的顺利进行奠定了基础。
2、烟酸衍生物抑制IDO1酶活性的IC50值测定
实验方法:
用KH2PO4(100mM,pH 6.5)缓冲溶液,根据IDO1的摩尔消光系数计算1μM蛋白在404nm紫外吸收值来准备蛋白样品。准备1.5mL的EP管,做好化合物各浓度梯度的标记;然后取1mL、1μM蛋白于EP管中,作为反应体系的体积;随后分别向其中加入亚甲基蓝、过氧化氢酶、L-抗坏血酸(用NaOH调pH至6.5),试剂终浓度分别为10μM、200μg/mL和10mM;再向每个管中加入对应浓度梯度的化合物并设置不加化合物空白孔,上下颠倒混合均匀后在37℃水浴锅中孵育10min;随后在动力学测试前加入100μM底物L-色氨酸,然后立即监测320nm处反应产物N'-甲酰犬尿氨酸的吸收值,反应时间为60s。实验选择100μM色氨酸浓度下的抑制率计算抑制剂的IC50值。
数据处理:
数据处理上,首先对各个反应的动力学实验数据进行线性拟合,求出初始速率V;然后根据公式计算出不同化合物浓度下对应的抑制率,以抑制率对烟酸衍生物抑制剂浓度的Log10值进行作图,根据IC50公式进行数据拟合,即可得到各化合物的IC50值。
实验结果:IC50值测定表明10个烟酸衍生物对IDO1均有抑制作用。化合物6、7、8、9、10上,它们的IC50值均在10μM左右。8个化合物均表现出比阳性对照化合物4-PI(IC50:49.03±6.67μM)更高的IDO1抑制效果,其中化合物9和10的效果最好,它们在最大浓度200μM的抑制率最高,而化合物9的抑制率可以达到90%。
表1.烟酸衍生物抑制IDO1金属酶的IC50和Ki值
3、烟酸衍生物抑制IDO1抑制常数Ki测定
实验方法与数据处理:
对同一种烟酸衍生物抑制剂分别在50μM、100μM和150μM三个底物浓度下进行平行的抑制活性动力学实验。首先对各个反应的动力学实验数据进行线性拟合,求出初始速率V,然后采用Cornish-Bowden作图法,在同一个数轴中以抑制剂浓度为横坐标,底物浓度与初始速率V的比值(S/V)为纵坐标,最后对三组数据进行线性拟合,拟合直线交点的绝对值即为抑制常数Ki,而通过交点Ki所处坐标轴的位置来判定抑制剂的抑制类型。导出的实验数据用Origin 7.5进行作图分析。
实验结果:
Ki值测定选择在100μM的浓度下抑制率在60%以上的化合物进行,分别是化合物2,4,5,8,9,10。实验分别用不同抑制剂浓度在50μM、100μM、150μM三种烟酸衍生物底物浓度下进行平行实验,以S/V对烟酸衍生物抑制剂浓度作图,三组数据线性拟合的直线交点的绝对值即为抑制常数Ki。
如表1所示,三种强IDO1烟酸衍生物抑制剂8(15.56μM),9(8.68μM)和10(9.93μM)的Ki值在15μM范围内。Ki值越低,则抑制效果越强,因此,烟酸衍生物抑制剂9对IDO1具有最强的抑制效果。以上的结果表明,两种含氟化合物9和10作为以3-吡啶丙酸为母核的化合物对IDO1抑制活性最强。两者的最低IC50和Ki约为10μM。抑制剂9的抑制效果效果最为显著主要由两方面原因促成,一方面,与其他抑制剂相比,只有9具有氧和三个氟原子,F的引入可以增强IDO1和抑制剂之间的氢键结合力。特别是,9含有三氟乙基,它可以显著提高抑制剂的结合能力。另一方面,9中的羧酸被氟取代,这增加了抑制剂的疏水性,并且有利于9占据IDO1的疏水腔。总之,含有容易形成氢键的元素,特别是含有三氟乙基的化合物,它们更具有抑制IDO1的潜在优势。
实施例2:烟酸衍生物对癌细胞IDO1酶抑制作用研究
1、实验试剂耗材
0.25×胰酶-EDTA、双抗(青霉素/链霉素)购自Gibco公司;1640培养基、FBS胎牛血清购自维森特生物技术(南京)有限公司;异丙醇、DMSO、冰醋酸、无水乙醇、硫酸铜购自国药集团化学试剂有限公司;Nalgene程序降温盒购自北京索莱宝科技有限公司;无菌PBS缓冲液、无菌0.22μm水相滤膜购自生工生物工程(上海)股份有限公司;CCK-8试剂盒购自碧云天生物技术有限公司;60mm和100mm细胞培养皿、细胞冻存管购自Corning公司;96孔板购自NEST公司;人***细胞(Hela)、人肝癌细胞(HepG-2)、人乳腺癌(MCF-7)、人正常肝细胞(L02)购自上海中科院细胞库;IFNγ购自Sigma-Aldrich公司;对-二甲氨基苯甲醛,三氯乙酸,4-苯基咪唑均购自阿拉丁试剂(上海)有限公司。
2、实验仪器
-80℃冰箱(安徽中科都菱商用电器股份有限公司);电热恒温水浴锅(上海科恒实业发展有限公司);立式压力蒸汽灭菌锅(上海博迅实业有限公司医疗设备厂);双人单面垂直送风洁净工作台(上海天恒医疗器械有限公司);二氧化碳培养箱(型号:BPN-50CH,上海一恒科学仪器有限公司);显微镜(上海光学仪器一厂);立式电冰箱(合肥美菱股份有限公司);离心机(Sorvall Legend Micro 17R/21R,Thermo Fisher Scientific);酶标仪(BioTek CytationTM 3)。
3、实验内容及实验方法
本实验采用IFNγ诱导癌细胞产生IDO1,从而进行活细胞水平上的IDO1抑制剂的活性检测。
实验第一天:将用100mm培养至一定细胞密度的HeLa、HepG-2和MCF-7癌细胞用胰蛋白酶消化,显微镜下观察,细胞形态变圆后用完全培养基中止消化,将细胞用移液器轻轻吹落,离心去除胰酶。以5×104个/mL的细胞数目接种到96孔板中并设置空白对照。将其放在37℃、5%CO2的二氧化碳培养箱中培养12小时。
实验第二天:将96孔板中的细胞换液并加入200μL培养基,随后在每个培养空分别加入终浓度位10ng/mL的IFNγ、100μM的色氨酸和不同浓度梯度的抑制剂,共同培养48h。抑制剂的终浓度分别为0μM、0.5μM、1μM、5μM、10μM、20μM、40μM、60μM、80μM、100μM、150μM、200μM。阳性对照药4-PI的终浓度分别为0μM、10μM、20μM、40μM、6μM、100μM、150μM、200μM。每个样品浓度复孔3个。
实验第四天:细胞加药培养48h后,每个培养孔取140μL上清至1.5mL离心管中,加入10μL 30%(w/v)的三氯乙酸溶液,在65℃水浴条件下孵育15min终止IDO1对色氨酸的催化反应,并使N′-甲酰犬尿氨酸转化为犬尿氨酸;随后10000rpm离心10min,再取100μL的上清溶液至新的96孔板中,加入相同体积的2%(w/v)对-二甲氨基苯甲醛的乙酸溶液混合,进行显示反应;最后采用酶标仪检测492nm处的吸收值,根据产物的量来计算IDO1酶的反应速率。数据导出为excel格式,然后用GraphPad 7.00作图。细胞实验进行两次技术重复。IDO1活细胞上的抑制率计算公式:Inhibition%=[1-(A/B)]×100%(1)(A表示含有抑制剂时的吸收值,B表示不含抑制剂时的吸收值。)
4、实验结果
为了评估烟酸衍生物对活细胞中IDO1酶的抑制活性,我们对实施例1酶抑制实验筛选的抑制率大于60%的六种抑制剂进行细胞实验分析,选用三种人源癌细胞系。首先测定了20μM相同抑制剂浓度下药物对三种癌细胞中IDO1的抑制率,实验结果如表2,在Hela细胞系中,9和10对IDO1的抑制率最高,分别为14.70%和20.06%,在HepG-2细胞系中,9和10同样产生了最好的抑制效果,抑制率分别为45.61%和29.52%,而在抑制剂在MCF-7细胞系中产生的抑制作用较弱,抑制剂9略微显著,为13.54%,其他5种抑制剂均在10%左右。我们用9和10抑制剂确定它们对HepG-2细胞的IDO1的EC50。结果表明,9和10的EC50值分别问11.04μM,14.06μM。其他抑制剂的EC50值均超过100μM(表2)。
表2、烟酸衍生物抑制人源癌细胞中IDO1抑制活性参数
实施例3:采用荷瘤鼠模型检测烟酸衍生物的抗肿瘤作用
动物
BALB/C普通小鼠,雄性,体重20-22g,7-8周龄,SPF级,购于上海斯莱克实验动物有限责任公司[实验动物质量合格证号:SCXK(沪)2007-0005]。
饲养条件
所有小鼠均自由觅食和饮水,在室温(25±2)℃下饲养。饲料及水均经高压灭菌处理,全部实验饲养过程为SPF级。
剂量设置
(1)烟酸衍生物(化合物9)设置1个剂量组20mg/kg;
(2)烟酸衍生物与cGAMP联合用药:烟酸衍生物20mg/kg+cGAMP20
mg/kg;
(3)烟酸衍生物与抗PD-L1联合用药:烟酸衍生物20mg/kg/天+抗PD-L1单抗,200μg/次,每周一次;
试验对照
阴性对照:生理盐水溶液
阳性对照:
(1)cGAMP,20mg/kg;
(2)抗PD-L1单抗,200μg/次,每周一次;
给药方法
给药途径:尾静脉注射
给药体积:100微升/只;给药次数:连续21天给药,每隔两天给药1次。
每组动物数:10只
小鼠结直肠癌细胞株CT26,小鼠乳腺癌细胞株4T1均购自中国科学院细胞库。
试验主要步骤
肿瘤模型鼠的建立与干预
细胞培养,传代,在细胞对数期收集细胞,做成浓度为每毫升(1.0×107)的细胞悬液,小鼠右前肢腋下注射0.2ml细胞悬液(细胞数目为2.0×106个/只),8天左右致瘤成功。按照两种小鼠肿瘤模型实验类别,分别随机均分6组,包括模型对照组、cGAMP阳性药对照组、抗-PD-L1阳性药对照组、烟酸衍生物9、烟酸衍生物9与cGAMP联合用药组、烟酸衍生物9与抗PD-L1单抗联合用药组。21天后,处死小鼠并称瘤体重量,计算抑瘤率。
分别制备小鼠结直肠癌细胞株CT26,移植到BalB/C普通小鼠,小鼠乳腺癌细胞株4T1,移植到BalB/C普通小鼠,观察不同药物抗肿瘤效果。
统计分析
数据用x±s表示,利用SPSS10.0软件进行处理,采用单因素方差分析(one-wayANOVA)检验比较各组瘤重差异的显著性,显著性水平a=0.05。
实验结果
小鼠皮下接种肿瘤细胞后制备成功皮下移植瘤模型,烟酸衍生物(化合物9)可明显抑制肿瘤生长,给药21天后的瘤重显著低于阴性对照模型组(P<0.05,P<0.01);烟酸衍生物(化合物9)联合cGAMP、烟酸衍生物(化合物9)联合抗PD-L1单抗联合用药组,均表现出比各自单一成分单独用药显著提高的抑制肿瘤药效作用。具体结果见表2-3。
表2.烟酸衍生物及其联合用药对小鼠结直肠癌细胞CT26皮下移植瘤的抑制作用
表3.烟酸衍生物及其联合用药对小鼠乳腺癌4T1皮下移植瘤的抑制作用
实施例4.烟酸衍生物小鼠急性毒性研究
实验方法:
ICR小鼠20只(购于上海斯莱克实验动物有限责任公司[实验动物质量合格证号:SCXK(沪)2007-0005]),雌雄各半,体重18~22g,动物以颗粒饲料喂养,自由摄食和饮水。
烟酸衍生物(化合物9)用生理盐水配制成浓度为200mg/mL的溶液。
ICR小鼠按体重单次腹腔注射2g/kg的新型复合物给药,观察给药后小鼠14天内的毒性反应及死亡情况。结果发现,小鼠单次腹腔注射给药后,小鼠活动正常。给药后14天内,小鼠未出现死亡,第15天,全部小鼠处死,解剖,肉眼检查各脏器,均未见明显病变。
实验结果:
上述急性毒性实验结果表明,腹腔给药最大耐受量MTD不低于2g/Kg,说明烟酸衍生物9的急性毒性低。
附图1:烟酸衍生物(1-10)结构式及其名称。
Claims (3)
1.烟酸衍生物作为抗肿瘤有效成分在制备抗肿瘤药物中的应用,所述的抗肿瘤药物应用于治疗结直肠癌、乳腺癌;所述烟酸衍生物的结构式为:
2.烟酸衍生物作为抗肿瘤有效成分与免疫通路STING激动剂联合在制备抗肿瘤药物中的应用,所述免疫通路STING激动剂为cGAMP;所述的抗肿瘤药物应用于治疗结直肠癌、乳腺癌,所述烟酸衍生物的结构为:
3.根据权利要求1所述的烟酸衍生物作为抗肿瘤有效成分在制备抗肿瘤药物中的应用,其特征在于,所述药物为药学上可接受的药物制剂。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011100808.9A CN114369060B (zh) | 2020-10-15 | 2020-10-15 | 吲哚胺2,3-双加氧酶抑制剂及其在制备抗肿瘤药物中的应用 |
PCT/CN2021/072121 WO2022077791A1 (zh) | 2020-10-15 | 2021-01-15 | 新型吲哚胺2,3-双加氧酶抑制剂及其在制备抗肿瘤药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011100808.9A CN114369060B (zh) | 2020-10-15 | 2020-10-15 | 吲哚胺2,3-双加氧酶抑制剂及其在制备抗肿瘤药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114369060A CN114369060A (zh) | 2022-04-19 |
CN114369060B true CN114369060B (zh) | 2023-11-03 |
Family
ID=81138649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011100808.9A Active CN114369060B (zh) | 2020-10-15 | 2020-10-15 | 吲哚胺2,3-双加氧酶抑制剂及其在制备抗肿瘤药物中的应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114369060B (zh) |
WO (1) | WO2022077791A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114886892B (zh) * | 2022-05-07 | 2023-09-12 | 四川大学 | 氧化吲哚螺双环[2,2,1]庚烷类化合物在制备治疗胃癌药物中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1623987A1 (de) * | 2004-08-02 | 2006-02-08 | Curacyte Discovery GmbH | Anellierte Pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und Pyrido[3',2':4,5]furo[3,2-d]pyrimidine |
CN101611018A (zh) * | 2006-11-10 | 2009-12-23 | 阿斯利康(瑞典)有限公司 | 具有Edg-I拮抗活性的杂环磺酰胺 |
WO2011081968A1 (en) * | 2009-12-31 | 2011-07-07 | Corning Incorporated | Pi3k modulators, rho kinase modulators and methods of identifying and using same |
CN103819393A (zh) * | 2010-03-01 | 2014-05-28 | 瑞科西有限公司 | 化合物及其治疗应用 |
WO2014081856A2 (en) * | 2012-11-20 | 2014-05-30 | Azzazy Hassan | Ligands that target hcv-e2 binding sites on cd81 and therapeutic methods using them |
WO2019005559A1 (en) * | 2017-06-28 | 2019-01-03 | Genentech, Inc. | INHIBITORS OF TDO2 AND IDO1 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10980807B2 (en) * | 2016-02-09 | 2021-04-20 | Inventisbio Llc | Inhibitor of indoleamine-2,3-dioxygenase (IDO) |
-
2020
- 2020-10-15 CN CN202011100808.9A patent/CN114369060B/zh active Active
-
2021
- 2021-01-15 WO PCT/CN2021/072121 patent/WO2022077791A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1623987A1 (de) * | 2004-08-02 | 2006-02-08 | Curacyte Discovery GmbH | Anellierte Pyrido[3',2':4,5]thieno[3,2-d]pyrimidine und Pyrido[3',2':4,5]furo[3,2-d]pyrimidine |
CN101611018A (zh) * | 2006-11-10 | 2009-12-23 | 阿斯利康(瑞典)有限公司 | 具有Edg-I拮抗活性的杂环磺酰胺 |
WO2011081968A1 (en) * | 2009-12-31 | 2011-07-07 | Corning Incorporated | Pi3k modulators, rho kinase modulators and methods of identifying and using same |
CN103819393A (zh) * | 2010-03-01 | 2014-05-28 | 瑞科西有限公司 | 化合物及其治疗应用 |
WO2014081856A2 (en) * | 2012-11-20 | 2014-05-30 | Azzazy Hassan | Ligands that target hcv-e2 binding sites on cd81 and therapeutic methods using them |
WO2019005559A1 (en) * | 2017-06-28 | 2019-01-03 | Genentech, Inc. | INHIBITORS OF TDO2 AND IDO1 |
Non-Patent Citations (5)
Title |
---|
An SAR study of hydroxy-trifluoromethylpyrazolines as inhibitors of Orai1-mediated store operated Ca2+ entry in MDA-MB-231 breast cancer cells using a convenient Fluorescence Imaging Plate Reader assay;Stevenson, Ralph J.,等;Bioorganic & Medicinal Chemistry;第26卷(第12期);第3406-3413页 * |
Hauck, Stefanie,等.Pyrazolo[1,5α]pyrimidines as a new class of FUSE binding protein 1 (FUBP1) inhibitors.Bioorganic & Medicinal Chemistry.2016,第24卷(第22期), 第5717-5729页. * |
Najlaa S. Al-Radad,等.Artichoke (Cynara scolymus L.,) mediated rapid analysis of silver nanoparticles and their utilisation on the cancer cell treatments.Journal of Computational and Theoretical Nanoscience.2018,第15卷(第06期),第1818-1829页. * |
Selected pharmacotherapy agents as antiproliferative and anti-inflammatory compounds;Mthanna AlKhalil,等;Drug Development Research;第81卷(第04期);第470-490页 * |
尼克酸治疗恶性黑素瘤的相关机制研究;陈龙,等;中国医疗美容;第09卷(第02期);第88-91页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114369060A (zh) | 2022-04-19 |
WO2022077791A1 (zh) | 2022-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10702527B2 (en) | Combination therapy of transcription inhibitors and kinase inhibitors | |
US10711036B2 (en) | MALT1 inhibitors and uses thereof | |
AU2019225166A1 (en) | Small molecules for inducing selective protein degradation and uses thereof | |
Hait et al. | A matter of life or death (or both): understanding autophagy in cancer | |
US20220401474A1 (en) | Hdac6-activated macrophages, compositions, and uses thereof | |
US11634450B2 (en) | DOT1L degraders and uses thereof | |
CN114369060B (zh) | 吲哚胺2,3-双加氧酶抑制剂及其在制备抗肿瘤药物中的应用 | |
US20210130324A1 (en) | Small molecules that block proteasome-associated ubiquitin receptor rpn13 function and uses thereof | |
US20220395509A1 (en) | A pyrazolopyrimidine derivative as a hck inhibitor for use in therapy, in particular myd88 mutated diseases | |
US20230405118A1 (en) | Stat-activated macrophages, compositions, and uses thereof | |
EP2030987B1 (en) | S-nitroso group-containing albumin, method for production, and anticancer agent | |
WO2017008736A1 (zh) | 抗体依赖性细胞介导的细胞毒性增强的奥法木抗体 | |
JP2002523468A (ja) | CaNBを含む薬物の組合せ物 | |
WO2020146561A1 (en) | Dot1l degraders and uses thereof | |
CN116057071B (zh) | 重组灵芝免疫调节蛋白新突变体及其应用 | |
CN115124619B (zh) | 临床血液免疫细胞的制备方法及其应用 | |
CN107737123B (zh) | 一种能杀伤肿瘤干细胞的癌症治疗药物及其应用 | |
CN114634551B (zh) | 多肽及其在制备拮抗野生型p53与MDM2结合的抗癌药物中的应用 | |
CN114712381B (zh) | Ak2基因在制备白血病诱导分化治疗药物中的应用 | |
WO2024060520A1 (zh) | 一种防治肿瘤的药物及其用途 | |
US20230058545A1 (en) | Hck as a therapeutic target in myd88 mutated diseases | |
CN117106007A (zh) | 裂环羽扇豆烷衍生物及其在制备多靶点肿瘤血管生成和侵袭转移抑制剂中的应用 | |
Xu et al. | Targeted inhibition of myeloid-derived suppressor cells by doxorubicin to enhance antigen-specific cytotoxic T lymphocytes killing neuroblastoma cells in vitro | |
CN115124618A (zh) | 一种自体血液分离的免疫细胞在治疗疾病中的应用 | |
CN116249534A (zh) | 嘧啶化合物的结晶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |